# A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

> **NCT02118337** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 97 (actual)

## Conditions studied

- Select Advanced Malignancies
- Kidney Cancer
- Clear Cell Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** MEDI0680
- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02118337
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-19
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-03-17
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118337, "A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02118337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*